These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 6861875

  • 1. Prevention and therapy with electrolectin of experimental autoimmune myasthenia gravis in rabbits.
    Levi G, Tarrab-Hazdai R, Teichberg VI.
    Eur J Immunol; 1983 Jun; 13(6):500-7. PubMed ID: 6861875
    [Abstract] [Full Text] [Related]

  • 2. Specificities of antibody to acetylcholine receptor in rabbits with experimental myasthenia gravis.
    Ueno S, Kang J, Takeuchi H, Takahashi M, Tarui S.
    Clin Exp Immunol; 1980 Jul; 41(1):13-8. PubMed ID: 6777100
    [Abstract] [Full Text] [Related]

  • 3. Monoclonal anti-acetylcholine receptor antibodies with differing capacities to induce experimental autoimmune myasthenia gravis.
    Gomez CM, Richman DP.
    J Immunol; 1985 Jul; 135(1):234-41. PubMed ID: 3873489
    [Abstract] [Full Text] [Related]

  • 4. Cytophilic antibodies in experimental autoimmune myasthenia gravis.
    Martinez RD, Tarrab-Hazdai R, Aharonov A, Fuchs S.
    J Immunol; 1977 Jan; 118(1):17-20. PubMed ID: 830746
    [Abstract] [Full Text] [Related]

  • 5. Oral administration of acetylcholine receptor: effects on experimental myasthenia gravis.
    Okumura S, McIntosh K, Drachman DB.
    Ann Neurol; 1994 Nov; 36(5):704-13. PubMed ID: 7979216
    [Abstract] [Full Text] [Related]

  • 6. [Clinical correlation of anti-receptor antibody titer, sensitivity to curare and electromyographic changes in experimental autoimmune myasthenia gravis].
    Chen SM.
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1990 Oct; 23(5):293-6, 320. PubMed ID: 2282884
    [Abstract] [Full Text] [Related]

  • 7. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
    Atassi MZ, Oshima M, Deitiker P.
    Crit Rev Immunol; 2001 Oct; 21(1-3):1-27. PubMed ID: 11642597
    [Abstract] [Full Text] [Related]

  • 8. Clonotypic analysis of anti-acetylcholine receptor antibodies from experimental autoimmune myasthenia gravis-sensitive Lewis rats and experimental autoimmune myasthenia gravis-resistant Wistar Furth rats.
    Zoda T, Yeh TM, Krolick KA.
    J Immunol; 1991 Jan 15; 146(2):663-70. PubMed ID: 1987281
    [Abstract] [Full Text] [Related]

  • 9. Animal models of myasthenia gravis.
    Christadoss P, Poussin M, Deng C.
    Clin Immunol; 2000 Feb 15; 94(2):75-87. PubMed ID: 10637092
    [Abstract] [Full Text] [Related]

  • 10. [Immunologic aspects of disorders of neuromuscular transmission. 2. Experimental autoimmune myasthenia gravis and the Lambert-Eaton myasthenic syndrome].
    Andreis I, Lovnićki TJ, Beara N, Taradi M.
    Lijec Vjesn; 1994 Feb 15; 116(5-6):158-61. PubMed ID: 7968205
    [Abstract] [Full Text] [Related]

  • 11. Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptors.
    Araga S, Galin FS, Kishimoto M, Adachi A, Blalock JB.
    J Immunol; 1996 Jul 01; 157(1):386-92. PubMed ID: 8683141
    [Abstract] [Full Text] [Related]

  • 12. Specific killing of lymphocytes that cause experimental autoimmune myasthenia gravis by ricin toxin-acetylcholine receptor conjugates.
    Killen JA, Lindstrom JM.
    J Immunol; 1984 Nov 01; 133(5):2549-53. PubMed ID: 6332854
    [Abstract] [Full Text] [Related]

  • 13. The thymus in myasthenia gravis. Changes typical for the human disease are absent in experimental autoimmune myasthenia gravis of the Lewis rat.
    Meinl E, Klinkert WE, Wekerle H.
    Am J Pathol; 1991 Nov 01; 139(5):995-1008. PubMed ID: 1951638
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Combined short-term immunotherapy for experimental autoimmune myasthenia gravis.
    Pestronk A, Drachman DB, Teoh R, Adams RN.
    Ann Neurol; 1983 Aug 01; 14(2):235-41. PubMed ID: 6354071
    [Abstract] [Full Text] [Related]

  • 16. The limitation of IL-10-exposed dendritic cells in the treatment of experimental autoimmune myasthenia gravis and myasthenia gravis.
    Xiao BG, Duan RS, Zhu WH, Lu CZ.
    Cell Immunol; 2006 Jun 01; 241(2):95-101. PubMed ID: 17005165
    [Abstract] [Full Text] [Related]

  • 17. Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment.
    Im SH, Barchan D, Fuchs S, Souroujon MC.
    J Clin Invest; 1999 Dec 01; 104(12):1723-30. PubMed ID: 10606626
    [Abstract] [Full Text] [Related]

  • 18. Immunotherapy for myasthenia gravis: a murine model.
    Christadoss P, Dauphinee MJ.
    J Immunol; 1986 Apr 01; 136(7):2437-40. PubMed ID: 2419435
    [Abstract] [Full Text] [Related]

  • 19. Experimental models of myasthenia gravis: lessons in autoimmunity and progress toward better forms of treatment.
    Pachner AR.
    Yale J Biol Med; 1987 Apr 01; 60(2):169-77. PubMed ID: 3495075
    [Abstract] [Full Text] [Related]

  • 20. Molecular aspects of experimental autoimmune myasthenia gravis.
    Fuchs S, Bartfeld D, Mochly-Rosen D, Schmidt-Hopfeld I, Tarrab-Hazdai R.
    Prog Clin Biol Res; 1981 Apr 01; 63():405-17. PubMed ID: 7031685
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.